Intech Investment Management LLC Has $5.04 Million Position in Collegium Pharmaceutical, Inc. $COLL

Intech Investment Management LLC grew its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 25.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 108,855 shares of the specialty pharmaceutical company’s stock after buying an additional 22,146 shares during the period. Intech Investment Management LLC owned approximately 0.34% of Collegium Pharmaceutical worth $5,040,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Federated Hermes Inc. raised its position in shares of Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 350 shares during the last quarter. Hantz Financial Services Inc. raised its position in shares of Collegium Pharmaceutical by 137.7% during the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 993 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Collegium Pharmaceutical by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after buying an additional 2,190 shares during the last quarter. Finally, NewEdge Advisors LLC raised its position in shares of Collegium Pharmaceutical by 304.6% during the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after buying an additional 2,294 shares during the last quarter.

Analysts Set New Price Targets

COLL has been the subject of a number of research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Truist Financial set a $58.00 price objective on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Insider Activity

In other news, EVP David Dieter sold 13,976 shares of the firm’s stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the sale, the executive vice president owned 77,071 shares of the company’s stock, valued at approximately $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Scott Dreyer sold 49,976 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the transaction, the executive vice president owned 71,770 shares of the company’s stock, valued at $2,900,225.70. This trade represents a 41.05% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.85% of the company’s stock.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $33.61 on Monday. Collegium Pharmaceutical, Inc. has a 12-month low of $28.74 and a 12-month high of $50.79. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The firm has a market capitalization of $1.09 billion, a PE ratio of 16.48 and a beta of 0.75. The firm has a 50-day moving average price of $34.12 and a 200 day moving average price of $41.37.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $193.52 million during the quarter, compared to analyst estimates of $184.47 million. During the same quarter in the prior year, the business posted $1.49 earnings per share. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. Research analysts anticipate that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.